Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 20/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 20/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 20/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 20/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001687 | 0.88 | PDK1 (0.44) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4499456 | 0.86 | PDK1 (0.48) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4490842 | 0.86 | PDK1 (0.48) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4482045 | 0.85 | KMT2A (0.43) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL4501832 | 0.83 | PTPN2 (0.36) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL4495254 | 0.76 | PTPN1 (0.42) | HSP90AA1 | |
| SCHEMBL5823772 | 0.76 | PDK1 (0.40) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4503844 | 0.74 | PDK1 (0.48) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4503005 | 0.74 | PDK1 (0.48) | PDK1PDK2PDK3PDK4HSP90AA1 | |
| SCHEMBL4491385 | 0.74 | PDK1 (0.42) | PDK1PDK2PDK3PDK4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006068928-A1 | PYRROLO[1,2-A]QUINOXALIN-5-(4H)-YL)SULFONYLS AND CARBONYLS AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | ESR1, GPER1, ESR2 | PDK1 1615/4885PDK2 1989/4885PDK3 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.